In this video, health-care analyst David Williamson walks investors through today's Aveo Pharmaceuticals (AVEO +0.00%) bloodbath. Shares are down 50% as an FDA advisory committee voted overwhelmingly against its drug candidate tivozanib. Find out why the decision shook out like it did, and if Aveo is a bad news buy after today's extreme plunge.
Shares plunge 50% as Aveo Pharmaceutical's kidney cancer drug gets a 13-1 "no" vote.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid